专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014145029A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES 审中-公开
标题翻译： N-ACYL-N' - （PYRIDIN-2-YL）URAAS和模拟展示抗癌和抗增殖活性
公开(公告)号：WO2014145029A2
公开(公告)日：2014-09-18
申请号：PCT/US2014029666
申请日：2014-03-14
申请人： DECIPHERA PHARMACEUTICALS LLC , CALDWELL TIMOTHY MALCOLM , SAMARAKOON THIWANKA , VOGETI LAKSHMINARAYANA , PATT WILLIAM C , AHN YUMI
发明人： CALDWELL TIMOTHY MALCOLM , SAMARAKOON THIWANKA , VOGETI LAKSHMINARAYANA , PATT WILLIAM C , AHN YUMI , FLYNN DANIEL L , KAUFMAN MICHAEL D
IPC分类号： A61F2/44
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D493/08
摘要： Described are compounds of Formula (I) which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.
摘要翻译：描述了通过抑制c-FMS（CSF-IR），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫性疾病和代谢性骨骼疾病中有用的式（I）化合物。这些化合物也用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。

2. 发明申请

WO2014145015A2 IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES 审中-公开
标题翻译：咪达洛芬和类似物展示抗癌和抗增生活性
公开(公告)号：WO2014145015A2
公开(公告)日：2014-09-18
申请号：PCT/US2014029650
申请日：2014-03-14
申请人： DECIPHERA PHARMACEUTICALS LLC , SAMARAKOON THIWANKA , CALDWELL TIMOTHY MALCOLM , VOGETI LAKSHMINARAYANA , AHN YUMI , PATT WILLIAM C , YATES KAREN M
发明人： SAMARAKOON THIWANKA , CALDWELL TIMOTHY MALCOLM , VOGETI LAKSHMINARAYANA , AHN YUMI , PATT WILLIAM C , YATES KAREN M , FLYNN DANIEL L , KAUFMAN MICHAEL D
IPC分类号： A61B17/00 , B25G1/02
CPC分类号： C07D417/14 , C07B59/002 , C07B2200/05 , C07D401/14 , C07D405/14 , C07D413/14
摘要： Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.
摘要翻译：描述了通过抑制c-FMS（CSF-IR），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫疾病和代谢性骨骼疾病中有用的式I化合物。这些化合物也用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。

3. 发明申请

WO2014145028A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES 审中-公开
标题翻译： N-ACYL-N' - （吡啶-2-基）尿素及类似物抗肿瘤和抗增殖活性
公开(公告)号：WO2014145028A2
公开(公告)日：2014-09-18
申请号：PCT/US2014029664
申请日：2014-03-14
申请人： DECIPHERA PHARMACEUTICALS LLC , CALDWELL TIMOTHY MALCOLM , PATT WILLIAM C , SAMARAKOON THIWANKA , VOGETI LAKSHMINARAYANA , YATES KAREN M
发明人： CALDWELL TIMOTHY MALCOLM , PATT WILLIAM C , SAMARAKOON THIWANKA , VOGETI LAKSHMINARAYANA , YATES KAREN M , FLYNN DANIEL L , KAUFMAN MICHAEL D
IPC分类号： A47C1/02 , A47B83/02 , A47C1/00
CPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： Described are compounds of Formula I, which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.
摘要翻译：描述了式I化合物，其通过抑制c-FMS（CSF-1R），c-KIT和/或PDGFR激酶而用于治疗癌症，自身免疫疾病和代谢性骨病。这些化合物还可用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其他哺乳动物疾病。

4. 发明申请

WO2014145025A3 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES 审中-公开
标题翻译： 2-AMINOPYRIMIDIN-6-ONES和模拟展示抗癌和抗增殖活性
公开(公告)号：WO2014145025A3
公开(公告)日：2015-01-08
申请号：PCT/US2014029661
申请日：2014-03-14
申请人： DECIPHERA PHARMACEUTICALS LLC , AHN YUMI , VOGETI LAKSHMINARAYANA , CALDWELL TIMOTHY MALCOLM
发明人： AHN YUMI , VOGETI LAKSHMINARAYANA , CALDWELL TIMOTHY MALCOLM , KAUFMAN MICHAEL D , FLYNN DANIEL L
IPC分类号： A61K31/4375
CPC分类号： C07D401/14 , A61K31/506 , C07D405/14
摘要： Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.
摘要翻译：描述了通过抑制c-FMS（CSF-IR），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫疾病和代谢性骨骼疾病中有用的式I化合物。这些化合物也用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。

5. 发明申请

WO2008033999A3 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译：激酶抑制剂用于治疗增殖性疾病
公开(公告)号：WO2008033999A3
公开(公告)日：2008-08-07
申请号：PCT/US2007078394
申请日：2007-09-13
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , PATT WILLIAM C
发明人： FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , PATT WILLIAM C
IPC分类号： A61K31/54
CPC分类号： C07D471/04 , C07D487/04
摘要： The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
摘要翻译：本发明涉及用于治疗各种疾病的新型激酶抑制剂和调节剂化合物。更具体地说，本发明涉及这样的化合物，激酶/化合物加合物，治疗疾病的方法以及合成该化合物的方法。优选地，所述化合物可用于调节Raf激酶及其疾病多晶型物的激酶活性。本发明化合物可用于治疗哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑素瘤，结肠直肠癌，卵巢癌，乳头状甲状腺癌，非小细胞肺癌和间皮瘤。本发明化合物还可用于治疗类风湿性关节炎和视网膜病，包括糖尿病视网膜神经病和黄斑变性。

6. 发明申请

WO2008033999A8 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译：用于治疗增殖性疾病的激素抑制剂
公开(公告)号：WO2008033999A8
公开(公告)日：2009-11-05
申请号：PCT/US2007078394
申请日：2007-09-13
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , PATT WILLIAM C
发明人： FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , PATT WILLIAM C
IPC分类号： A61K31/54
CPC分类号： C07D471/04 , C07D487/04
摘要： The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
摘要翻译：本发明涉及可用于治疗各种疾病的新型激酶抑制剂和调节剂化合物。更具体地，本发明涉及这些化合物，激酶/化合物加合物，治疗疾病的方法和化合物的合成方法。优选地，所述化合物可用于调节Raf激酶及其疾病多形体的激酶活性。本发明的化合物可用于治疗哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑素瘤，结肠直肠癌，卵巢癌，甲状腺乳头状癌，非小细胞肺癌和间皮瘤。本发明的化合物还可用于治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性。

7. 发明申请

WO2008034008A3 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译：用于治疗增殖性疾病的激素抑制剂
公开(公告)号：WO2008034008A3
公开(公告)日：2008-07-10
申请号：PCT/US2007078408
申请日：2007-09-13
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , KAUFMAN MICHAEL D , PATT WILLIAM C , PETILLO PETER A
发明人： FLYNN DANIEL L , KAUFMAN MICHAEL D , PATT WILLIAM C , PETILLO PETER A
IPC分类号： A61K31/54 , A61K39/395
CPC分类号： A61K31/4375 , A61K31/519 , C07D471/04
摘要： The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
摘要翻译：本发明涉及可用于治疗各种疾病的新型激酶抑制剂和调节剂化合物。更具体地，本发明涉及这些化合物，激酶/化合物加合物，治疗疾病的方法和化合物的合成方法。优选地，所述化合物可用于调节Raf激酶及其疾病多形体的激酶活性。本发明的化合物可用于治疗哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑素瘤，结肠直肠癌，卵巢癌，甲状腺乳头状癌，非小细胞肺癌和间皮瘤。本发明的化合物还可用于治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性。

8. 发明申请

WO2012019015A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES 审中-公开
标题翻译：治疗失语性疾病和其他增殖性疾病的方法和组合
公开(公告)号：WO2012019015A2
公开(公告)日：2012-02-09
申请号：PCT/US2011046609
申请日：2011-08-04
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , BOOTH RICHARD JOHN
发明人： FLYNN DANIEL L , PETILLO PETER A , KAUFMAN MICHAEL D , BOOTH RICHARD JOHN
IPC分类号： A61K39/395 , A61K31/454 , A61K31/506 , A61K31/519 , A61P11/00 , A61P19/00 , A61P35/00
CPC分类号： A61K31/454 , A61K31/506 , A61K31/519
摘要： Compounds of the present invention find utility in the treatment of hyperproliferative diseases, including autoimmune diseases and other diseases characterized by hypervascularization or proliferation of myeloid, mast cells, fibroblasts, synoviocytes, or monocytes; mammalian cancers and especially human cancers including but not limited to melanomas; a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof including BCR-ABL kinase and polymorphs thereof; a disease caused by FLT-3 kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof; a disease caused by cMET kinase, oncogenic forms thereof, aberrant fusion proteins thereof including TPR-MET; a disease caused by KDR kinase or PDGFR kinases; a disease caused by HER kinases, oncogenic forms thereof and polymorphs thereof; a disease caused by RET kinase, oncogenic forms thereof, aberrant fusion proteins thereof; a disease caused by c-FMS kinase, oncogenic forms thereof and polymorphs thereof; a disease caused by a c-KIT kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof; and diseases caused by any of the foregoing kinases, oncogenic forms thereof, and aberrant fusion proteins thereof, including but not limited to, chronic myelogenous leukemia, acute lymphocytic leukemia, acute myeloid leukemia, other myeloproliferative disorders, a disease caused by metastasis of primary solid tumors to secondary sites, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, mesothelioma, hypereosinophilic syndrome, a disease caused or maintained by pathological vascularization, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, i.e. diabetic retinopathy and age-related macular degeneration, non small cell lung cancer, breast cancers, kidney cancers, colon cancers, cervical carcinomas, papillary thyroid carcinoma, melanomas, autoimmune diseases including rheumatoid arthritis, multiple sclerosis, lupus, asthma, human inflammation, rheumatoid spondylitis, ostero-arthritis, asthma, gouty arthritis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, reperfusion injury, neural trauma, neural ischemia, psoriasis, restenosis, chronic obstructive pulmonary disease, bone resorptive diseases, bone cancer, graft-versus-host reaction, Chron's disease, ulcerative colitis, inflammatory bowel disease, pyresis, gastrointestinal stromal tumors, mastocytosis, mast cell leukemia, and combinations thereof.
摘要翻译：本发明的化合物可用于治疗过度增殖性疾病，包括自身免疫疾病和其它特征在于骨髓，肥大细胞，成纤维细胞，滑膜细胞或单核细胞的高血管形成或增殖的疾病; 哺乳动物癌症，特别是人类癌症，包括但不限于黑素瘤; 由c-ABL激酶，其致癌形式引起的疾病，异常融合蛋白，包括BCR-ABL激酶及其多态性; 由FLT-3激酶，其致癌形式，异常融合蛋白及其多态性引起的疾病; 由cMET激酶引起的疾病，其致癌形式，异常融合蛋白，包括TPR-MET; 由KDR激酶或PDGFR激酶引起的疾病; 由HER激酶，其致癌形式及其多晶型物引起的疾病; 由RET激酶，其致癌形式，异常融合蛋白引起的疾病; 由c-FMS激酶，其致癌形式及其多形体引起的疾病; 由c-KIT激酶，其致癌形式，异常融合蛋白及其多态性引起的疾病; 以及由上述激酶，其致癌形式及其异常融合蛋白引起的疾病，包括但不限于慢性骨髓性白血病，急性淋巴细胞性白血病，急性骨髓性白血病，其他骨髓增生性疾病，由原发性转移引起的疾病肿瘤到继发部位，胶质母细胞瘤，卵巢癌，胰腺癌，前列腺癌，肺癌，间皮瘤，嗜酸性粒细胞综合征，由病理性血管形成引起或维持的疾病，以过度增生为特征的眼病，导致失明，包括各种视网膜病变，即糖尿病性视网膜病变和年龄相关黄斑变性，非小细胞肺癌，乳腺癌，肾癌，结肠癌，宫颈癌，甲状腺乳头状癌，黑素瘤，自身免疫性疾病，包括类风湿性关节炎，多发性硬化症，狼疮，哮喘，人类炎症，类风湿性脊椎炎，关节炎，哮喘，痛风脓毒病，败血症，败血症休克，内毒素休克，革兰氏阴性败血症，中毒性休克综合征，成人呼吸窘迫综合征，中风，再灌注损伤，神经创伤，神经缺血，牛皮癣，再狭窄，慢性阻塞性肺病，骨吸收性疾病，，移植物抗宿主反应，克隆氏病，溃疡性结肠炎，炎症性肠病，胃肠道间质瘤，肥大细胞增多症，肥大细胞白血病及其组合。

9. 发明申请

WO2006014290A3 ANTI-INFLAMMATORY MEDICAMENTS 审中-公开
标题翻译：抗炎药物
公开(公告)号：WO2006014290A3
公开(公告)日：2006-04-27
申请号：PCT/US2005023100
申请日：2005-06-30
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , PETILLO PETER A
发明人： FLYNN DANIEL L , PETILLO PETER A
IPC分类号： A61K31/4184 , A61K31/426 , A61K31/4745 , A61K31/496 , A61K31/517 , A61K31/53 , A61K31/5377 , C07D231/40 , C07D401/04 , C07D401/12 , C07D403/10 , C07D403/12 , C07D417/10 , C07D417/12 , C07D417/14 , C07D237/04
CPC分类号： A61K31/4184 , A61K31/426 , A61K31/4745 , A61K31/496 , A61K31/517 , A61K31/53 , A61K31/5377 , C07C271/56 , C07C2601/10 , C07D231/38 , C07D231/40 , C07D285/10 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14
摘要： Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
摘要翻译：提供了新的化合物和使用这些化合物治疗炎性病症的方法。在优选的实施方案中，调节p38激酶蛋白的活化状态包括使激酶蛋白与新化合物接触的步骤。

10. 发明申请

WO2004060305A3 ANTI-CANCER MEDICAMENTS 审中-公开
标题翻译：抗癌药物
公开(公告)号：WO2004060305A3
公开(公告)日：2005-02-10
申请号：PCT/US0341425
申请日：2003-12-26
申请人： DECIPHERA PHARMACEUTICALS LLC , FLYNN DANIEL L , PETRILLO PETER A
发明人： FLYNN DANIEL L , PETRILLO PETER A
IPC分类号： A61K20060101 , A61K31/4152 , A61K31/4184 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/505 , A61K31/506 , C07D231/14 , C07D231/40 , C07D239/42 , C07D249/12 , C07D285/10 , C07D295/10 , C07D401/04 , C07D401/14 , C07D403/10 , C07D403/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/12 , C07D417/14
CPC分类号： C07D239/42 , C07D295/10 , C07D401/04 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要： Novel compounds and methods of using those compounds for the treatment of oncological conditions are provided. In a preferred embodiment, modulation of the activation states of abl or bcr-abl a-kinase proteins comprises the step of contacting the kinase proteins with the novel compounds.
摘要翻译：提供了新的化合物和使用这些化合物治疗肿瘤病症的方法。在优选的实施方案中，abl或bcr-ablα激酶蛋白的活化状态的调节包括使激酶蛋白与新化合物接触的步骤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式